$1.15▾ 5.74%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-0.9%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
60 Degrees Pharmaceuticals, Inc.'s earnings-quality signal is not available yet. Revenue is contracting year over year. Very low debt relative to its asset base.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish0 neutral1 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.